IGM Biosciences, Inc. (IGMS)
Au 14, 2025 - IGMS was delisted (reason: acquired by Concentra Biosciences)
1.270
-0.030 (-2.31%)
Inactive · Last trade price on Aug 13, 2025
IGM Biosciences Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for IGM Biosciences stock had an average target of 6.00, with a low estimate of 1.00 and a high estimate of 22.
Price Target: $6.00 (+372.44%)
Analyst Consensus: Hold
* Price targets were last updated on Jun 11, 2025.
Analyst Ratings
The average analyst rating for IGM Biosciences stock from 8 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 7 | 7 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $2 → $1 | Hold | Maintains | $2 → $1 | -21.26% | Jun 11, 2025 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades n/a | Sell → Hold | Upgrades | n/a | n/a | Jan 13, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $48 → $2 | Strong Buy → Hold | Downgrades | $48 → $2 | +57.48% | Jan 10, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $12 → $2 | Hold | Maintains | $12 → $2 | +57.48% | Jan 10, 2025 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $27 → $2.5 | Strong Buy → Hold | Downgrades | $27 → $2.5 | +96.85% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
9.44M
from 2.68M
Increased by 252.44%
Revenue Next Year
13.83M
from 9.44M
Increased by 46.48%
EPS This Year
-1.30
from -3.24
EPS Next Year
-1.19
from -1.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.2M | 25.2M | |||
| Avg | 9.4M | 13.8M | |||
| Low | 1.7M | 3.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 841.4% | 167.1% | |||
| Avg | 252.4% | 46.5% | |||
| Low | -36.0% | -67.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.09 | -0.06 | |
| Avg | -1.30 | -1.19 | |
| Low | -2.29 | -2.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.